Analysts Offer Insights on Healthcare Companies: aTyr Pharma (NASDAQ: LIFE) and Cooper Co (NYSE: COO)

By Jason Carr

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on aTyr Pharma (NASDAQ: LIFE) and Cooper Co (NYSE: COO).

aTyr Pharma (NASDAQ: LIFE)

In a report released yesterday, Matthew Luchini from BMO Capital reiterated a Hold rating on aTyr Pharma (NASDAQ: LIFE), with a price target of $4. The company’s shares opened today at $3.50.

According to TipRanks.com, Luchini is ranked 0 out of 5 stars with an average return of -17.4% and a 18.8% success rate. Luchini covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Alder Biopharmaceuticals, and Spark Therapeutics.

Currently, the analyst consensus on aTyr Pharma is Hold and the average price target is $4, representing a 14.3% upside.

In a report issued on May 11, J.P. Morgan also reiterated a Hold rating on the stock.
Cooper Co (NYSE: COO)

BMO Capital analyst Joanne Wuensch reiterated a Buy rating on Cooper Co (NYSE: COO) yesterday and set a price target of $220. The company’s shares opened today at $217.79, close to its 52-week high of $218.17.

According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 8.8% and a 70.5% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Cooper Co has an analyst consensus of Moderate Buy, with a price target consensus of $214.33.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.